4.7 Review

SARS-CoV-2 variants, spike mutations and immune escape

Journal

NATURE REVIEWS MICROBIOLOGY
Volume 19, Issue 7, Pages 409-424

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41579-021-00573-0

Keywords

-

Categories

Funding

  1. UK Medical Research Council (MRC), UK Research and Innovation
  2. UK National Institute of Health Research
  3. Genome Research Limited
  4. MRC [MR/R024758/1, MC_UU_12014/12]
  5. UK Biotechnology and Biological Sciences Research Council [BB/R012679/1]
  6. G2P-UK National Virology Consortium - UK Research and Innovation [MR/W005611/1]
  7. Wellcome Trust [220977/Z/20/Z, 206298/Z/17/Z]
  8. European Research Council [725422]
  9. Wellcome Trust [220977/Z/20/Z] Funding Source: Wellcome Trust
  10. MRC [MR/R024758/1] Funding Source: UKRI
  11. European Research Council (ERC) [725422] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

The evolution of SARS-CoV-2 has been characterized by the emergence of mutations and variants that impact virus characteristics. Manufacturers are preparing for possible updates to vaccines in response to changes in the virus population, and it is crucial to monitor genetic and antigenic changes alongside experiments to understand the impacts of mutations.
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been characterized by the emergence of mutations and so-called variants of concern that impact virus characteristics, including transmissibility and antigenicity. In this Review, members of the COVID-19 Genomics UK (COG-UK) Consortium and colleagues summarize mutations of the SARS-CoV-2 spike protein, focusing on their impacts on antigenicity and contextualizing them in the protein structure, and discuss them in the context of observed mutation frequencies in global sequence datasets. Although most mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome are expected to be either deleterious and swiftly purged or relatively neutral, a small proportion will affect functional properties and may alter infectivity, disease severity or interactions with host immunity. The emergence of SARS-CoV-2 in late 2019 was followed by a period of relative evolutionary stasis lasting about 11 months. Since late 2020, however, SARS-CoV-2 evolution has been characterized by the emergence of sets of mutations, in the context of 'variants of concern', that impact virus characteristics, including transmissibility and antigenicity, probably in response to the changing immune profile of the human population. There is emerging evidence of reduced neutralization of some SARS-CoV-2 variants by postvaccination serum; however, a greater understanding of correlates of protection is required to evaluate how this may impact vaccine effectiveness. Nonetheless, manufacturers are preparing platforms for a possible update of vaccine sequences, and it is crucial that surveillance of genetic and antigenic changes in the global virus population is done alongside experiments to elucidate the phenotypic impacts of mutations. In this Review, we summarize the literature on mutations of the SARS-CoV-2 spike protein, the primary antigen, focusing on their impacts on antigenicity and contextualizing them in the protein structure, and discuss them in the context of observed mutation frequencies in global sequence datasets.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available